Trastuzumab deruxtecan is highly effective against HER2-positive gastric cancer, HER2-mutated non-small-cell lung cancer, and HER2-expressing metastatic colorectal cancer 5-7. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.